Increasing evidence shows that inhibition of EZH2 alone has limited anti-cancer effects in the clinic.113, 114, 115 In an open-label, multicenter, dose-increasing, phase 1 clinical study, 8 of 21 patients with B-cell non-Hodgkin lymphoma (38%) and 2 of 43 solid tumor patients (5%) were observed persistent objective responses, including complete responses.116. Here, EZH2 is linked to cancer.